Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs Vitrectomy for PDR Vitreous Hemorrhage
NCT02858076Phase 3Completed
- Sponsor
- Jaeb Center for Health Research
- Start
- Nov 2016
- Primary completion
- Jan 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of aflibercept in proliferative diabetic retinopathy (PDR) and Vitreous hemorrhage (VH) (2 arms), sponsored by Jaeb Center for Health Research. Primary endpoint: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) at 24 weeks. Started Nov 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)Vitreous hemorrhage (VH)
Beyond the preview
Go deeper on NCT02858076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858076.